



Beneficial Effect of Probiotic *Saccharomyces Boulardii* in Management of Acute Diarrhoea of Children: A Randomized Controlled Trial

¹Gajanan M. Sirsat and ²Rajesh Saraf

^{1,2}Department of Pediatrics, Dr. Ulhas Patil Medical College, Jalgaon (MH), India

OPEN ACCESS

Key Words

Acute diarrhea, *saccharomyces boulardii*, probiotics, degree dehydration, rehydration therapy

Corresponding Author

Gajanan M. Sirsat,
Jai Gajanan Children Superspeciality
Hospital, Ghatpuri Naka, Khamgaon
Dist-Buldhana, Maharashtra, India
gajanansirsat@yahoo.com

Author Designation

^{1,2}Assistant Professor

Received: 17 August 2024

Accepted: 18 September 2024

Published: 28 October 2024

Citation: Gajanan M. Sirsat and Rajesh Saraf, 2024. Beneficial Effect of Probiotic *Saccharomyces Boulardii* in Management of Acute Diarrhoea of Children: A Randomized Controlled Trial. Res. J. Med. Sci., 18: 500-504, doi: 10.36478/makrjms.2024.11.500.504

Copy Right: MAK HILL Publications

ABSTRACT

Although oral rehydration solution remains the mainstay in the treatment of acute diarrhoea, this therapy does not reduce the duration of diarrhoea, prompting a growing interest in adjunctive treatments. The present study demonstrated that oral treatment with *S. boulardii* diminished the duration of diarrhoea from the second day after the beginning of the intervention as compared with a control group. To assess effects of *Saccharomyces boulardii* in acute diarrhoea. In terms of reduce duration and severity of diarrhoea. with use of *Saccharomyces boulardii* in dosage of 50 mg/kg/ day in two divided doses daily for five days in acute childhood diarrhoea. This was a prospective randomized control trial study that was conducted in with strength of 290 cases, aged 2 months to 5 years from both sex, presenting with acute watery diarrhoea at Dr. Ulhas Patil Medical College, Jalgaon (MH), were enrolled in the study. Informed consent was taken from the parents before enrolment. Information was collected in the form of questionnaire that included age, sex, anthropometric data and systemic details. The study population was randomly divided into 2 groups using random numbers table with 145 children in each group. Degree of dehydration of study population was assessed by WHO guidelines, including general condition, eagerness to drink, sunken eyes and skin turgor. Children were categorized as having mild dehydration, moderate dehydration and severe dehydration. This randomized controlled trial was conducted at Dr. Ulhas Patil Medical College, Jalgaon (MH) for 1 year duration. Non-probability, purposive sampling was employed as sampling technique. Probiotic *Saccharomyces boulardii* administration as add-on medication reduced the duration of illness after approximately 24 hours shows significant difference in our study favouring the use of probiotic *Saccharomyces* in treatment group as compared to the control group. *Saccharomyces boulardii* shortens the duration of diarrhea, normalizes stool consistency, reduces the frequency of diarrhoea, the effect was more significant from 3rd day onwards. The appearance of the 1st semiformed stool was earlier after giving *Saccharomyces boulardii*. The mean number of stools per day were significantly reduced after administration of *Saccharomyces boulardii*. The results were obvious from 2nd day onwards. The use of *S. boulardii* along with rehydration therapy main stay of treatment in diarrheal diseases in children. So its use should be encouraged in order to reduce both mortality and morbidity in diarrhea illness.

INTRODUCTION

Diarrheal diseases in children is the second most common leading cause of under 5 mortality accounting for about 18% over worldwide. The disease causes more than 2.5 billion episodes of illness and 1.5 million annual deaths globally. Most of these deaths occur in developing countries. According to United Nation report more children under 5 years died in India than anywhere else in world in 2011, that is 1.7 million children^[1]. The role of saccharomyces boulardii as a probiotics in diarrhoea depends on many factors including intrinsic property of a yeast, its pharmacokinetics, product to product variation, stability, number of strain used in probiotic preparation and dose of probiotic use. Probiotics have moderate clinical benefits in the treatment of acute diarrhoea in children, the result should be interpreted with caution because of methodological limitation of the studies and that more research is needed. An increasing number of potential health benefits are being attributed to probiotics treatment. However , only a limited number have been confirmed in well designed and conducted randomized controlled trials (RCTs) and even less in the paediatrics population. Saccharomyces boulardii is a live yeast used extensively as a probiotics and often marketed as a dietary supplement. An increasing number of potential health benefits are being attributed to the use of Saccharomyces boulardii in acute diarrhoea in children, however, limited numbers have been confirmed in a well designed and conducted randomized controlled trials. The role of saccharomyces boulardii in treatment of acute diarrhoea has received considerable attention in recent year.so this study aim at the efficacy of saccharomyces boulardii in acute diarrhea.

MATERIALS AND METHODS

This was a prospective randomized control trial study that was conducted in with strength of 290 cases , aged 2 months to 5 years from both sex, presenting with acute watery diarrhoea at Dr. Ulhas Patil Medical College, Jalgaon (MH), were enrolled in the study. Informed consent was taken from the parents before enrolment. Information was collected in the form of questionnaire that included age, sex, anthropometric data and systemic details. The study population was randomly divided into 2 groups using random numbers table with 145 children in each group. Degree of dehydration of study population was assessed by WHO guidelines, including general condition, eagerness to drink, sunken eyes and skin turgor. Children were categorized as having mild dehydration, moderate dehydration and severe dehydration. A written approval was taken from guardians of the patients before conducting the study.

The study population in Probiotic group was managed by ORS and orally administered S. boulardii (250 mgBD)

diluted in water or mixed with semi-solid food. In our study dose of Saccharomyces used-50 mg/kg/day. The control group children were managed by ORS alone. The active treatment period was 5 days. All study participants were examined on day 1 and were monitored for next 5 days. Efficacy was assessed by improved consistency of stools (formed stools) and decrease in duration of diarrhoea and reduced frequency of stools less than 3 per 24 hours. All children completed the stipulated 5-day study period and no one was lost to follow up. The relevant tests of significance such as "chi square test" were applied for qualitative variables (dehydration status, vomiting and frequency and consistency of stool) and quantitative variables (age, weight and duration of diarrhoea) respectively. A p value of <0.05 or <0.001 was considered as significant depending on the data analyzed.

RESULTS AND DISCUSSIONS

In our study the stool consistency were comparable in both groups on day 1. However stool consistency-formed stool significantly was noted in probiotic group on day 3 (56.5%) comparable with control group(37.4%). Thus improvement was significantly rapid in the probiotic compared with control group.

Table 1: Comparison on Basis of Stool Consistency-Formed Stool in Between 2 Group

Stool consistency	Formed Stool	
(DAYS)	Probiotic	Control
1	5 (3.5%)	1 (0.7%)
2	40 (27.5%)	31 (21.4%)
3	82 (56.5%)	54 (37.4%)
4	108 (74.5%)	95 (65.5%)
5	145 (100%)	145 (100%)

X^2 test=41.39 , DF =4, P value <0.001 (Singnificant) Since p value is <0.001 ,it proves that difference is statistically significant.

The stool frequency were comparable in both groups on day 1 and 2. However decrease in frequency significantly was noted in probiotic group on day 3 (43%) comparable with control group(23%).Thus improvement was significantly rapid in the probiotic compared with control group.

Table 2: Comparison on Basis of Stool Frequency (<3 Stools Per Day) in Both Groups

Frequency (in Days)	<3 Stools/Day	
	Probiotic	Control
1	3(2%)	2(1.5%)
2	31(22%)	36(25.5%)
3	63(43%)	34(23%)
4	25(17%)	26(18%)
5	23(16%)	47(32%)
Total	145(100%)	145(100%)

X^2 test= 38.2, DF=4, P value<0.001(significant) Since p value is <0.001,it proves that difference is statistically significant.

It can be clear that the mean duration of diarrhoea less than or equal to 3 days of intervention seen in probiotic group (67%) as compared to control group(49%). Thus overall response to probiotic on decreasing frequency stool on 3 day of intervention shows significant difference.

Table 3: Mean Duration of Diarrhoea After Intervention in Both Groups

Mean Duration of Diarrhoea After Intervention in Both Group			
Group	>3DAYS	>3DAYS	Total
Probiotic	97(67%)	48(33%)	145
Control	72(49%)	73(51%)	145
Total	169	121	290

χ^2 test = 17.242, DF=1, P value < 0.01 (Significant) Since p value is less than 0.01, it proves that difference is statistically significant.

It can be observed that the appearance of first semiformal stool in probiotic group is somewhat earlier (38%) as compared to control group(26%). Thus, it shows that there is significant improvement in stool consistency-semiformed stool in probiotic group than in control group.

Table 4 : Comparison on Basis of Appearance of 1st Semiformed Stool in Probiotic and Control Group

Appearance of 1 st Semiformed Stool			
Group	Before 3rd Day	On or After 3rd Day	Total
Probiotic	55(38%)	90(62%)	145
Control	37(26%)	108(74%)	145
Total	92	198	290

χ^2 test =11.7, DF=1, P value <0.001 (Significant) Since p value is <0.001, it proves that difference is statistically significant.

There is difference between children rotavirus antigen test positive having decrease diarrhea frequency in probiotic and control group. About 64% in probiotic group as compared with 39% control group having decreased diarrhoea after 3 days of intervention.

Table 5: Comparison on Basis of Rota Virus Antigen Positive Having Decrease Frequency of Diarrhoea After 3 Days of Interventions

Reduced Frequency of Diarrhoea After 3rd Day of Intervention			
Group	yes	no	Total
Probiotic	28(36%)	60(64%)	88
Control	47(61%)	30(39%)	77
Total	75	90	165

χ^2 test=14.14, DF=1, P value <0.001 (Significant) The p value is <0.001 which is statistically significant.

It is shown that there is significant difference in the probiotic and control group in reducing diarrhoea frequency in probiotic group(71%) as comparable to control group(47%) in patients with lactose intolerance on 5th day of intervention.

Table 6: Comparison Between Lactose Intolerance Patients Having Decrease Frequency of Diarrhea After 5 Days of Intervention

Lactose Intolerance Patients Having Decrease Frequency of Diarrhoea After 5 Days of Intervention			
Group	Yes	NO	Total
Probiotic	27(71%)	11(29%)	38
Control	14(47%)	16(53%)	27
Total	41	27	68

χ^2 test =4.16, DF=1, P value <0.05 (Significant) Since p value is less than 0.05, it proves that difference is statistically significant.

It is shown that there is significant difference in the probiotic and control group in reducing diarrhoea frequency in probiotic group(62%) as comparable to control group(45%) having required hospitalisation <3 days.

Table 7: Comparison on Basis of Median Days of Hospitalisation Required in Both Groups

Hospitalisation (Days)			
Group	<3 Days	>3 Days	Total
Probiotic	90(62%)	55(38%)	145
Control	65(45%)	80(55%)	145
Total	155	135	290

χ^2 test =17.4, DF=1, P value <0.001 (Significant) Since p value is less than 0.001, it proves that difference is statistically significant.

There are numerous randomized, double blind placebo controlled studies showing the efficacy of *Saccharomyces Boulardii* in treatment and prevention of many gastrointestinal disorders. The consistency of stool i.e. time from start of treatment until the appearance of first normal formed stool was an important outcome. A randomized controlled trial was conducted by Htwe and colleagues^[2] in children with AWD. The children received ORS with and without *S. boulardii* (50 mg/kg/day, twice daily) for 5 days. Stool consistency showed no difference between the two groups on day 2. But on day 3, it returned to normal in 76% of active treatment group versus 24% of control group. Another study done on Clinical Efficacy of Use of Probiotic "*Saccharomyces Boulardii*" A study done in Children with Acute Watery Diarrhoea Atiya Khan showed that there is no significant difference on first two days of intervention but on 3rd there was markedly increase in number of patients in probiotic group (48%) as compared with control group(21%) showing change in stool consistency.

In our study, the appearance 1st semiformal stool in probiotic group on 3rd day was 56.5% as comparable with control group 37.4%. The results were much better on 4th day. The overall assessment of clinical response showed a remarkable reduction in mean duration of diarrhoea as a result of appearance of formed stool in

S. boulardii group compared to control group. On basis of clinical trial and Study done by Atiya khan and colleagues^[3] the results regarding stool frequency on 3rd day, 54% children of the treatment group were observed passing <3 stools per day as compared to 30% in control group.




Fig.1: Comparison Between the Studies for Stool Consistency-Formed Stool in Between the Probiotic and Control Groups.

Another double blind, placebo controlled study conducted by Naflesia B. O., Correa^[4]. It showed that 2 days after the beginning of the intervention, the frequency of patients who remained with diarrhoea was lower in the probiotic group when compared with the placebo group. The difference between the 2 groups was maintained by day 3 of intervention, with 50% of patients with diarrhoea in the group treated with *S. boulardii* and 32% in the placebo group.

In our study stool frequency decreased from 2nd day onwards, it was significantly reduced on 3rd day. Stool frequency on 3rd day 43% as comparable to control group it is 23%. It clearly shows that probiotic group had significant improvement as compared to control group.

The mean duration of diarrhoea less than or equal to 3 days in Probiotic group was 67% whereas it is compared with that of control group 49%. This signifies that there is significant decrease in duration of diarrhoea in terms of decrease in frequency less than 3 stools per day and time from start of treatment until appearance of first normal stool.

In 2007, Szajewska and colleagues conducted a meta-analysis study^[5] in children with acute diarrhoea, comparing *S. boulardii* to placebo or no intervention. The combined data from these studies provide pool weighted mean difference of reduction of approximately 1 days in favour of treatment group. These results clearly correlate with our study. Similar beneficial effect of reduction in duration of diarrhoea by a little more than one day was seen in children treated with *S. boulardii* by Guandalini^[6]. Another

study Vandeplas^[7] also showed a decrease in mean duration of diarrhoea by 1.3 days in *S. boulardii* group compared to control groups in children with acute diarrhoea. Another study conducted in Turkey showed the duration of diarrhoea as significantly reduced (more than one day) in *S. boulardii*.

Group compared with placebo Probiotic group in children having acute diarrhoea [Kurugol Z, Koturoglu^[8]. The randomised control trial study done by Atiya Khan, Tahir Javed^[3] showed that the mean duration of diarrhoea in Probiotic group was 3.43 days, compared with 4.50 days in the Control group. The Probiotic group (*S. boulardii*) had shown reduction in the duration of diarrhoea by approximately 1.1 day in children with acute watery diarrhoea. A randomized controlled trial was conducted by Htwe and colleagues^[2] in children with AWD. The children received ORS with and without *S. boulardii*, (250 mg twice daily) for 5 days. The mean duration of diarrhoea was 3.08 days in *S. Boulardii* group as compared to 4.68 day of control. In one randomized control trial conducted by Naflesia B.O. Corre[^]a,-Francisco^[9]. when the children pertaining to the 2 types of intervention were separated into rotavirus positive patients and rotavirus negative patients, the beneficial effect resulting from probiotic treatment was observed essentially for patients presenting with rota negative cases with 29%of children who remained with diarrhoea in the group treated with *S. boulardii* and 64% in the placebo group. In patients with rotavirus positive cases, 41.2% of children treated with *S. boulardii* remained with diarrhoea, whereas in the placebo group, this frequency was 54.3% (Naflesia B.O. Corre[^]a, Francisco J.)^[9] In our study There is difference between children rotavirus antigen test positive having decrease diarrhea frequency in probiotic and control group. About 64% in probiotic group as compared with 39% control group having decreased diarrhoea after 3days of intervention.

The assumption was that the presence of lactase producing bacteria in the yogurt, especially *Lactobacillus acidophilus*, contributed to the digestion and absorption of lactose (Levri km, ketvertis k, deramo m)^[10]. It was also found that the presence of *Lactobacillus bulgaricus* and *Streptococcus thermophilus*, *Saccharomces boulardii* alleviate lactose intolerance through their ability to produce lactase enzyme (McDonough FE, Hitchins AD)^[11] Based on the mentioned data, it is clear that there is obvious role of *saccharomyces boulardii* in treatment of lactose intolerance.

In our study, it is shown that there is significant difference in the probiotic and control group in

reducing diarrhoea frequency in probiotic group(62%) as comparable to control group(45%)having hospitalisation required less than 3 days.

In 2007, Szajewska, Graff S. and colleagues conducted a meta-analysis of the results from five studies comparing *S. boulardii* to placebo or no intervention^[12]. A total of 619 children were enrolled in these trials, with *S. boulardii* doses of 250-600 mg/day or placebo given for 4-6 days. Four studies along with this included the duration of diarrhoea as an outcome, with all demonstrating a significant reduction with treatment and hospital stay. Single studies used in this analysis also documented a reduction in the risk of diarrhoea lasting more than 7 days, as well as a reduction in length of hospital stay.

CONCLUSION

We Conclude that Concurrent Therapeutic Use of *S. Boulardii* Showed that :

- *Saccharomyces boulardii* shortens the duration of diarrhea, normalizes stool consistency. The appearance of the 1st semiformal stool was earlier after giving *Saccharomyces boulardii*.
- *Saccharomyces boulardii* reduces the frequency of diarrhoea, the effect was more significant from 3rd day onwards. The mean number of stools per day were significantly reduced after administration of *Saccharomyces boulardii*. The results were obvious from 2nd day onwards.
- The benefit of *Saccharomyces boulardii* was more in terms of controlling frequency and duration of diarrhoea in rotavirus antigen positive group. The result of *Saccharomyces boulardii* was more significant in patients having lactose intolerance. Patients having lactose intolerance were having reduced frequency of diarrhoea earlier than the control group.
- The main advantage of *Saccharomyces boulardii* was it reduces the median days of hospitalisation by reducing frequency and duration of diarrhoea.

Recommendations: In our study, *S. boulardii* shows key role in management of diarrhea .It safe and efficacious way to manage diarrhea with probiotics. Thus

Probiotics should used as far as possible in community health sector ,these measures definitely will reduce mortality and morbidity resulting from diarrhea diseases.

REFERENCES

1. Bhutta, Z.A., 2011. Acute Gastroenteritis in Children. In: Nelson textbook of Pediatrics., Kaliegmman, R.M., B.F. Stanton, J.W. Geme, N.F. Schor and R.E. Behrman, (Eds.), WB Saunders Company, Philadelphia, ISBN-13: 9780323529501, 0 pp: 67-68.
2. Htwe, K., K.S. Yee and M. Tin,et al., 2008. Effect of *Saccharomyces boulardii* in the treatment of acute watery diarrhea in Myanmar children: a randomized controlled study. *Am J Trop Med Hyg.*, 78: 214-216.
3. Atiya, K. and J. Tahir, 2012. Clinical Efficacy of Use of Probiotic "*Saccharomyces Boulardii*" In Children with Acute Watery Diarrhea.
4. Szajewska, H., A. Skorka and M. Dylag, 2007. Meta-analysis: *Saccharomyces boulardii* for treating acute diarrhoea in children. *Aliment. Pharmacol. amp Ther.*, 25:
5. Guandalini, S., 2008. Probiotics for Children With Diarrhea. *J. Clin. Gastroenterol.*, Vol. 42 .10.1097/mcg.0b013e3181674087.
6. Vandenplas, Y., O. Brunser and H. Szajewska, 2009. *Saccharomyces boulardii* in childhood. *Eur. J. Pediatr.s*, 168: 253-265.
7. Kurugöl, Z. and G. Koturoglu, 2005. Effects of *Saccharomyces boulardii* in children with acute diarrhoea. *Acta Paediatrica*, 94: 44-47.
8. Corrêa, N.B.O., F.J. Penna, F.M.L.S. Lima, J.R. Nicoli and L.A.P. Filho, 2011. Treatment of Acute Diarrhea With *Saccharomyces boulardii* in Infants. *J. Pediatr. Gastroenterol. Nutr.*, 53:.
9. McDonough, F.E., A.D. Hitchins, N.P. Wong, P. Wells and C.E. Bodwell, 1987. Modification of sweet acidophilus milk to improve utilization by lactose-intolerant persons. *Am J Clin Nutr.*, 45: 470-474.
10. Graff, S., J.C. Chaumeil, P. Boy, R. Lai-Kuen and C. Charrueau, 2008. Formulations for Protecting the Probiotic *Saccharomyces boulardii* from Degradation in Acidic Condition. *Bio. Pharm. Bull.*, 31: 266-272.